july 2016-PROTELICA ANNOUNCES STRATEGIC PARTNERSHIP WITH SINOBIOWAY
-PROTELICA ANNOUNCES STRATEGIC PARTNERSHIP WITH SINOBIOWAY Where Biotech Innovation meets drug development, manufacturing and commercialization in the Chinese pharmaceutical market Burlingame, CA, July 25 2016 – Protelica, Inc., a global biotechnology company focused on the development of Pronectin™ therapeutics, announced an equity investment and strategic partnership with Beijing Sinobioway Group Company, Limited (Sinobioway), a China-based investor group. The proceeds will be used to accelerate the development of Protelica’s Pronectin™ therapeutic platform. This strategic investment will also advance Protelica’s plans to collaboratively develop biotherapeutics with biopharmaceutical companies in China to address the growing demand for innovative therapeutic products in the Chinese pharmaceutical market. As part of the deal, Protelica and Sinobioway will also establish joint operations with facilities in Hefei, China to develop, manufacture and commercialize the Pronectin™ therapeutics. "With its innovative technology platform that includes novel protein therapeutics, DNA mutagenesis, protein engineering, novel Pronectin libraries, and an additional platform for stabilizing protein structures, Protelica is a great addition to our organization and will accelerate our pipeline of drug candidates for the Chinese market and the rest of the world,” said Professor Ahiua Pan, Chairman of Sinobioway, one of the three Sinobioway founders and world renowned for his Bioeconomics Theories. "We have found a formidable partner for our innovative protein engineering platform", declares Dr. Roberto Crea, Protelica founder and CEO." Our discovery engine, based upon strong and proprietary technologies, has now achieved a critical importance in conjunction with the powerful manufacturing capacity, clinical development and marketing presence provide by Sinobioway in China." "Our immediate focus will be the selection of potential protein therapeutics for a quick and thorough preclinical evaluation with Sinobioway to compete in the area of cancer immune therapy and future protein drug generation based upon antibody mimics” continues Dr. Crea.
About Pronectin™ Therapeutics Pronectins™ are an emerging, proprietary protein therapeutic class that can be designed to address a broad range of diseases. They are based on human fibronectin, an extracellular protein that is naturally abundant in human serum. The intrinsic properties of a Pronectins™ align with the properties needed to make a successful drug, including high potency, specificity, stability, favorable half-life, and high-yield production. Pronectins™ are designed using Protelica’s patented protein design engine, to achieve high potency and specificity for a therapeutic target while simultaneously selecting for ideal pharmaceutical product characteristics. Protelica is able to screen billions of unique Pronectin™ scaffolds for each drug discovery program to redirect naturally occurring human fibronectin to act as a protein therapeutic against a specific target. Protelica is the exclusive developer of Pronectins™ and solely owns the Pronectin™ patent estate containing issued and pending patent properties to fundamental Pronectin™ molecules. Since Pronectins™ have a different origin than antibodies, they are not bound by traditional antibody patents. In addition, Protelica has more than 70 issued and pending patents relating to Pronectins™ and its related protein engineering technology platform.
About Beijing SinoBioway Group Company, Limited Sinobioway is the largest biotech organization in China that includes more than 100 affiliates. Sinobioway Group Co., Ltd. (Sinobioway), founded in 1992, is one of the three main industrial groups affiliated with Peking University. Sinobioway is mainly engaged in bioeconomy system establishment and bio-industry development. It primarily invests in biomedicine, bioagriculture, bioenergy, bioenvironment, bioservices, biomanufacturing and biointelligence. Biologic therapeutics is a particular focus of Sinobioway in its plans to develop and commercialize new medicines. Sinobioway is constructing a large biologics production facility, with a long-term capability goal of 100 production lines, in the planned 20 billion RMB bio-economic zone under construction in Hefei. The company has become a flagship enterprise in China’s bioindustry and has the potential to become one of the most competitive corporate groups in the world.
About Protelica Protelica is focused on generating novel drugs through the discovery, development, and commercialization of its broadly applicable new therapeutic class, Pronectins™. The company has a pipeline Pronectins™ products in preclinical research across multiple therapeutic areas. Pronectins™ are designed and optimized using Protelica’s patented protein design engine that uniquely enables rapid optimization of protein therapeutics. Protelica was founded by Dr. Roberto Crea, who has provided innovative ideas for drug discovery and optimization since his first involvement with Genentech in 1977, as the first Director of DNA Chemistry and through his 30 years of entrepreneurial career. For more information, please visit http://www.protelica.com/.